Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Citius Pharmaceuticals Inc (CTXR) vs FTAI Aviation Ltd (FTAI) Price & Performance

Citius Pharmaceuticals IncTrade
FTAI Aviation LtdTrade

Price performance (Past 24H)

Key statistics

Citius Pharmaceuticals Inc vs FTAI Aviation Ltd — how do they compare? Citius Pharmaceuticals Inc trades at $0.76 (market cap $20.01M), while FTAI Aviation Ltd trades at $229.37 (market cap $23.17B). The key difference: FTAI Aviation Ltd is far larger — about 1157.9× Citius Pharmaceuticals Inc's market cap, and FTAI Aviation Ltd pays a 0.89% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.

CTXRFTAI
Market Cap
$20.01M$23.17B
Sector
HealthIndustrials
52-Week High
$1.82$310.04
52-Week Low
$0.48$140.40
Enterprise Value
$16.23M$26.29B
Dividend Yield
0.89%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Citius Pharmaceuticals Inc

CTXR is trading at $0.7126, up 5.26% today, with strong technical momentum showing bullish moving average signals. The company shows significant revenue growth potential with LYMPHIR commercialization expanding, though currently operates at substantial losses with a -823% net income margin. Analyst sentiment remains overwhelmingly positive with 83% buy ratings, reflecting optimism about the oncology pipeline and recent commercial progress.

The investment case hinges on successful LYMPHIR commercialization offsetting current losses, with strong institutional support providing runway. Key risks include execution challenges in scaling operations and the capital-intensive nature of biopharmaceutical development. The stock presents high-risk, high-reward potential for investors comfortable with clinical-stage biotech volatility.

FTAI Aviation Ltd

FTAI Aviation trades at $229.01, up 6.52% today, with a neutral technical signal and bearish moving averages. The stock shows strong profitability with a 15.94% net margin and 167.93% ROE, but valuation ratios are elevated (P/E 49.26, P/B 57.36). Recent Q2 2026 earnings missed expectations at $1.13 per share versus $1.38 expected, though revenue grew to $3.1B in 2026. The company announced a strategic collaboration for Boeing 737-800 freighters and a $1.465B gas turbine order, signaling growth initiatives.

Outlook remains positive with 100% analyst buy ratings and a $341.67 consensus price target, implying 49% upside. Key risks include earnings misses, declining EBITDA margins, and negative operating cash flow. The power segment's data center potential offers growth, but execution on guidance and leasing transition are critical for sustained performance.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Citius Pharmaceuticals Inc

Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.

Read more on CTXR

About FTAI Aviation Ltd

FTAI Aviation owns and maintains a fleet of commercial aircraft and engines. It focuses on the specialized maintenance of the CFM56 engine, helping airlines reduce costs through efficient asset management.

Read more on FTAI